IL-15: Targeting CD8+ T cells for immunotherapy

Cytotherapy

Volumn 7, Issue 1, 2005, Pages 23-35

  Diab, A ^a   Cohen, A D ^a,b   Alpdogan, O ^a   Perales, Miguel Angel ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

IL 15; Immunotherapy; Tumor; Vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; CD8 ANTIGEN; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 2; MONOCLONAL ANTIBODY; TETANUS TOXOID;

ADOPTIVE IMMUNOTHERAPY; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELL MATURATION; CELL SURVIVAL; CLOSTRIDIUM TETANI; DENDRITIC CELL; DRUG TARGETING; GLIOBLASTOMA; GRAFT VERSUS HOST REACTION; GROWTH INHIBITION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNE DEFICIENCY; IN VITRO STUDY; INFLUENZA; INFLUENZA VIRUS; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; LUNG METASTASIS; LYMPHOCYTE TRANSFER; MACROPHAGE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PLEIOTROPY; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TETANUS; TUMOR IMMUNITY; TUMOR REJECTION;

EID: 17444398212     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240510018037     Document Type: Review

References (153)

1. Atkins MB. Interleukin-2: clinical applications. Semin Oncol 2002;29:12-7.
2. Arduino RC, Nannini EC, Rodriguez-Barradas M et al. CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies. Clin Infect Dis 2004;39: 115-22.
3. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4.
4. Hoffman DM, Gitlitz BJ, Belldegrun A et al. Adoptive cellular therapy. Semin Oncol 2000;27:221-33.
5. Grabstein KH, Eisenman J, Shanebeek K et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994;264:965-8.
6. Burton JD, Bamford RN, Peters C et al. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA 1994;91:4935-9.
7. Bamford RN, Grant AJ, Burton JD et al. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA 1994;91:4940-4.
8. Anderson DM, Johnson L, Glaccum MB et al. Chromosomal assignment and genomic structure of IL15. Genomics 1995;25: 701-6.
9. Krause H, Jandrig B, Wernicke C et al. Genomic structure and chromosomal localization of the human interleukin 15 gene (IL-15). Cytokine 1996;8:667-74.
10. Waldmann T, Tagaya Y, Bamford R. Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol 1998;16:205-26.
11. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87: 6934-8.
12. Bazan JF. Haemopoietic receptors and helical cytokines. Immunol Today 1990;11:350-4.
13. Pettit DK, Bonnert TP, Eisenman J et al. Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling. J Biol Chem 1997;272:2312-8.
14. Carson WE, Giri JG, Lindemann MJ et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994;180:1395-403.
15. He YW, Malek TR. The structure and function of gamma c-dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis. Crit Rev Immunol 1998;18: 503-24.
16. Uribe L, Weinberg KI. X-linked SCID and other defects of cytokine pathways. Semin Hematol 1998;35:299-309.
17. Asao H, Okuyama C, Kumaki S et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001;167:1-5.
18. Giri JG, Kumaki S, Ahdieh M et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J 1995;14:3654-63.
19. Anderson DM, Kumaki S, Ahdieh M et al. Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J Biol Chem 1995;270:29862-9.
20. Tagaya Y, Burton JD, Miyamoto Y et al. Identification of a novel receptor/signal transduction pathway for IL-15/T in mast cells. EMBO J 1996;15:4928-39.
21. Masuda A, Matsuguchi T, Yamaki K et al. Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-xL expression. J Biol Chem 2001;276:26107-13.
22. + T cells is dispensable for T cell memory. Proc Natl Acad Sci USA 2003;100:4724-9.
23. Dubois S, Mariner J, Waldmann TA et al. IL-15Ralpha recycles and presents IL-15 in trans to neighboring cells. Immunity 2002;17:537-47.
24. Schluns KS, Klonowski KD, Lefrancois L. Transregulation of memory CD8 T-cell proliferation by IL-15Ralpha+ bone marrow-derived cells. Blood 2004;103:988-94.
25. Burkett PR, Koka R, Chien M et al. Coordinate expression and trans presentation of interleukin (IL)-15R{alpha} and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med 2004;200:825-34.
26. Koka R, Burkett P, Chien M et al. Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J Immunol 2004;173:3594-8.
27. Lin JX, Leonard WJ. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev 1997;8:313-32.
28. Taniguchi T, Miyazaki T, Minami Y et al. IL-2 signaling involves recruitment and activation of multiple protein tyrosine kinases by the IL-2 receptor. Ann NY Acad Sci 1995;766:235-44.
29. Ihle JN, Witthuhn BA, Quelle FW et al. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 1995;13: 369-98.
30. Miyazaki T, Kawahara A, Fujii H et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 1994;266:1045-7.
31. Lin JX, Migone TS, Tsang M et al. The role of shared receptor motifs and common Star proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 1995;2:331-9.
32. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999;17:19-49.
33. Miyazaki T, Liu ZJ, Kawahara A et al. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck co-operate in hematopoietic cell proliferation. Cell 1995;81:223-31.
34. Bulfone-Paus S, Bulanova E, Pohl T et al. Death deflected: IL-15 inhibits TNF-alpha-mediated apoptosis in fibroblasts by TRAF2 recruitment to the IL-15Ralpha chain. FASEB J 1999;13:1575-85.
35. Pereno R, Gaggero A, Scudeletti M et al. IL-15/IL-15R alpha intracellular trafficking in human cells and protection from apoptosis. Ann NY Acad Sci 1999;876:236-45.
36. Doherty TM, Seder RA, Sher A. Induction and regulation of IL-15 expression in murine macrophages. J Immunol 1996;156: 735-41.
37. Leclercq G, Debacker V, de Smedt M et al. Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells. J Exp Med 1996; 184:325-36.
38. Mohamadzadeh M, McGuire MJ, Dougherty I et al. Interleukin-15 expression by human endothelial cells: up-regulation by ultraviolet B and psoralen plus ultraviolet A treatment. Photodermatol Photoimmunol Photomed 1996;12:17-21.
39. Ozawa A, Tada H, Sugawara Y et al. Endogenous IL-15 sustains recruitment of IL-2Rbeta and common gamma and IL-2-mediated chemokine production in normal and inflamed human gingival fibroblasts. J Immunol 2004;173:5180-8.
40. Mohamadzadeh M, Takashima A, Dougherty I et al. Ultraviolet B radiation up-regulates the expression of IL-15 in human skin. J Immunol 1995;155:4492-6.
41. Ge N, Nishioka Y, Nakamura Y et al. Synthesis and secretion of interleukin-15 by freshly isolated human bronchial epithelial cells. Int Arch Allergy Immunol 2004;135:235-42.
42. Reinecker HC, MacDermott RP, Mirau S et al. Intestinal epithelial cells both express and respond to interleukin 15. Gastroenterology 1996;111:1706-13.
43. Bamford RN, Battiata AP, Burton JD et al. Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region/IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. Proc Natl Acad Sci USA 1996;93:2897-902.
44. Tagaya Y, Bamford RN, DeFilippis AP et al. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 1996;4:329-36.
45. Lodolce JP, Burkett PR, Koka RM et al. Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev 2002; 13:429-39.
46. Musso T, Calosso L, Zucca M et al. Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood 1999; 93:3531-9.
47. Neely GG, Robbins SM, Amankwah EK et al. Lipopolysaccharide-stimulated or granulocyte-macrophage colony-stimulating factor-stimulated monocytes rapidly express biologically active IL-15 on their cell surface independent of new protein synthesis. J Immunol 2001;167:5011-7.
48. Curotto de Lafaille MA, Lafaille JJ. CD4(+) regulatory T cells in autoimmunity and allergy. Curr Opin Immunol 2002; 14:771-8.
49. Willerford DM, Chen J, Ferry JA et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995;3:521-30.
50. Sadlack B, Merz H, Schorle H et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
51. Marks-Konczalik J, Dubois S, Losi JM et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA 2000;97:11445-50.
52. Li XC, Demirci G, Ferrari-Lacraz S et al. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med 2001;7: 114-8.
53. Kennedy MK, Glaccum M, Brown SN et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000;191:771-80.
54. Schluns KS, Williams K, Ma A et al. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol 2002;168:4827-31.
55. Becker TC, Wherry EJ, Boone D et al. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 2002;195:1541-8.
56. Goldrath AW, Sivakumar PV, Glaccum M et al. Cytokine requirements for acute and basal homeostatic proliferation of naive and memory CD8(+) T cells. J Exp Med 2002;195: 1515-22.
57. Tan JT, Ernst B, Kieper WC et al. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8(+) cells but are not required for memory phenotype CD4(+) cells. J Exp Med 2002;195:1523-32.
58. + memory T cells by opposing cytokines. Science 2000;288:675-8.
59. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 2001;14:105-10.
60. Lodolce JP, Boone DL, Chai S et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998;9:669-76.
61. Nishimura H, Yajima T, Naiki Y et al. Differential roles of interleukin 15 mRNA isoforms generated by alternative splicing in immune responses in vivo. J Exp Med 2000;191: 157-70.
62. + T cells. J Exp Med 2001;193:219-31.
63. Hiromatsu T, Yajima T, Matsuguchi T et al. Overexpression of interleukin-15 protects against Escherichia coli induced shock accompanied by inhibition of tumor necrosis factor-alpha-induced apoptosis. J Infect Dis 2003;187:1442-51.
64. + T cells following a microbe exposure. J Immunol 2002;168:1198-203.
65. Yajima T, Nishimura H, Wajjwalku W et al. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int J Cancer 2002;99:573-8.
66. Sprent J, Surh CD. Generation and maintenance of memory T cells. Curr Opin Immunol 2001;13:248-54.
67. + T cells in vivo by IL-15. Immunity 1998;8:591-9.
68. + T cells. Proc Natl Acad Sci USA 2004;101:15154-19.
69. Tan JT, Dudl E, LeRoy E et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci USA 2001;98:8732-7.
70. Schluns KS, Kieper WC, Jameson SC et al. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000;1:426-32.
71. Prlic M, Lefrancois L, Jameson SC. Multiple choices: regulation of memory CD8 T cell generation and homeostasis by interleukin (IL)-7 and IL-15. J Exp Med 2002;195:F49-52.
72. Kieper WC, Tan JT, Bondi-Boyd B et al. Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8(+) T cells. J Exp Med 2002; 195:1533-9.
73. Suzuki H, Duncan GS, Takimoto H et al. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain. J Exp Med 1997;185:499-505.
74. + hematopoietic progenitor cells. Blood 1996; 87:2632-40.
75. Mingari MC, Vitale C, Cantoni C et al. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. Eur J Immunol 1997; 27:1374-80.
76. Cooper MA, Bush JE, Fehniger TA et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002;100:3633-8.
77. Ranson T, Vosshenrich CA, Corcuff E et al. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 2003;101: 4887-93.
78. Ranson T, Vosshenrich CA, Corcuff E et al. IL-15 availability conditions homeostasis of peripheral natural killer T cells. Proc Natl Acad Sci USA 2003;100:2663-8.
79. Prlic M, Blazar BR, Farrar MA et al. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med 2003;197:967-76.
80. Matsuda JL, Gapin L, Sidobre S et al. Homeostasis of V alpha 14i NKT cells. Nat Immunol 2002;3:966-74.
81. Carson WE, Fehniger TA, Haldar S et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 1997;99:937-43.
82. Kundig TM, Schorle H, Bachmann MF et al. Immune responses in interleukin-2-deficient mice. Science 1993;262: 1059-61.
83. Maki K, Sunaga S, Komagata Y et al. Interleukin 7 receptor-deficient mice lack gammadelta T cells. Proc Natl Acad Sci USA 1996;93:7172-7.
84. Evans R, Fuller JA, Christianson G et al. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cell Immunol 1997;179:66-73.
85. Ross ME, Caligiuri MA. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 1997;89:910-8.
86. Fehniger TA, Shah MH, Turner MJ et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999;162:4511-20.
87. Waldmann TA. IL-15 in the life and death of lymphocytes: immunotherapeutic implications. Trends Mol Med 2003;9: 517-21.
88. Mitsuyasu R. Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency vilrus-infected patients. J Infect Dis 2002;185(suppl 2):S115-22.
89. Bernstein ZP, Porter MM, Gould M et al. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 1995;86:3287-94.
90. Emery S, Capra WB, Cooper DA et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis 2000;182:428-34.
91. + lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis 2003; 187:320-5.
92. Perales MA, Skolnik PR, Lieberman J. Effect of interleukin 12 on in vitro HIV type 1 replication depends on clinical stage. AIDS Res Hum Retroviruses 1996;12:659-68.
93. Mastroianni CM, d'Ettorre G, Forcina G et al. Teaching tired T cells to fight HIV: time to test IL-15 for immunotherapy? Trends Immunol 2004;25:121-5.
94. Chehimi J, Starr SE, Frank I et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994;179:1361-6.
95. d'Ettorre G, Forcina G, Lichtner M et al. Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients. Aids 2002;16:181-8.
96. Amicosante M, Poccia F, Gioia C et al. Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection. J Infect Dis 2003;188: 661-5.
97. Ahmad R, Sindhu ST, Toma E et al. Studies on the production of IL-15 in HIV-infected/AIDS patients. J Clin Immunol 2003;23:81-90.
98. Torti C, Cologni G, Uccelli MC et al. Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART). Viral Immunol 2004;17:279-86.
99. Borrow P, Lewicki H, Wei X et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLS) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-11.
100. Chitnis V, Pahwa R, Pahwa S. Determinants of HIV-specific CD8 T-cell responses in HIV-infected pediatric patients and enhancement of HIV-gag-specific responses with exogenous IL-15. Clin Immunol 2003;107:36-45.
101. Lubong R, Ng HL, Uittenbogaart CH et al. Culturing of HIV-1-specific cytotoxic T lymphocytes with interleukin-7 and interleukin-15. Virology 2004;325:175-80.
102. + effector-memory T cells. Int Immunol 2003;15:49-58.
103. + T cells exhibit markedly reduced levels of Bcl-2 and Bcl-xL. J Immunol 2004;172:4444-53.
104. Lum JJ, Schnepple DJ, Nie Z et al. Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity. J Virol 2004;78:6033-42.
105. Kim JJ, Trivedi NN, Nottingham LK et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998;28:1089-03.
106. Xin KO, Hamajima K, Sasaki S et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 1999;17:858-66.
107. Moore AC, Kong WP, Chakrabarti BK et al. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J Virol 2002; 76:243-50.
108. McKee HJ, T'Sao PY, Vera M et al. Durable cytotoxic immune responses against gp120 elicited by recombinant SV40 vectors encoding HIV-1 gp120+/-IL-15. Genet Vaccines Ther 2004; 2:10.
109. Oh S, Berzofsky JA, Burke DS et al. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci USA 2003;100:3392-7.
110. Small TN, Papadopoulos EB, Boulad F et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999;93:467-80.
111. Storek J, Dawson MA, Storer B et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97:3380-9.
112. McGlave PB, Shu XO, Wen W et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000;95:2219-25.
113. Katsanis E, Xu Z, Panoskaltsis-Mortari A et al. IL-15 administration following syngeneic bone marrow transplantation prolongs survival of lymphoma bearing mice. Transplantation 1996;62:872-5.
114. Alpdogan O, Eng JM, Muriglan SJ et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 2005;105:865-73.
115. Kumaki S, Minegishi M, Fujie H et al. Prolonged secretion of IL-15 in patients with severe forms of acute graft-versus-host disease after allogeneic bone marrow transplantation in children. Int J Hematol 1998;67:307-12.
116. Blaser BW, Roychowdhury S, Kim DJ et al. Donor derived IL-15 is critical for acute allogeneic graft-versus-host disease. Blood 2005;105:894-901.
117. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994;180:1-4.
118. Perales MA, Blachere NE, Engelhorn ME et al. Strategies to overcome immune ignorance and tolerance. Semin Cancer Biol 2002;12:63-71.
119. Chang DZ, Lomazow W, Joy Somberg C et al. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 2004;9:207-15.
120. Brentjens RJ, Latouche JB, Santos E et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003;9:279-86.
121. Wagner HJ, Sili U, Gahn B et al. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy 2003;5:231-40.
122. Yamaguchi T, Suzuki Y, Katakura R et al. Interleukin-15 effectively potentiates the in vitro tumor-specific activity and proliferation of peripheral blood gammadeltaT cells isolated from glioblastoma patients. Cancer Immunol Immunother 1998;47: 97-103.
123. Wysocka M, Benoit BM, Newton S et al. Enhancement of the host immune responses in cutaneous T cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 2004;104:4142-9.
124. + T cells. Proc Natl Acad Sci USA 2004;101:1969-74.
125. Wu JD, Higgins LM, Steinle A et al. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004;114:560-8.
126. Kobayashi H, Dubois S, Sato N et al. The role of trans-cellular IL-15-presentation in the activation of NK-mediated killing, which leads to enhanced tumor immunesurveillance. Blood 2005;105:721-7.
127. Munger W, DeJoy SQ, Jeyaseelan R et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 1995;165:289-93.
128. Lasek W, Basak G, Switaj T et al. Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice. Cancer Immunol Immunother 2004;53:363-72.
129. Roychowdhury S, May KF, Jr, Tzou KS et al. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res 2004;64:8062-7.
130. Meazza R, Lollini PL, Nanni P et al. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int J Cancer 2000;87:574-81.
131. + T cells. Int J Mol Med 2004; 14:571-6.
132. Villinger F, Miller R, Mori K et al. IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques. Vaccine 2004;22: 3510-21.
133. Cui FD, Asada H, Jin ML et al. Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice. Gene Ther 2005;12:160-8.
134. + T cell responses by DNA vaccination. J Mol Med 2003;81:91-101.
135. Kirman I, Vainer B, Nielsen OH. Interleukin-15 and its role in chronic inflammatory diseases. Inflamm Res 1998;47:285-9.
136. Waldmann T. The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases. Arthritis Res 2002; 4(suppl 3):S161-7.
137. McInnes IB, Leung BP, Sturrock RD et al. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997;3:189-95
138. McInnes IB, al-Mughales J, Field M et al. The role of interieukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996;2:175-82.
139. Thurkow EW, van der Heijden IM, Breedveld FC et al. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol 1997;181: 444-50.
140. Agostini C, Trentin L, Facco M et al. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol 1996;157:910-8.
141. Agostini C, Trentin L, Perin A et al. Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. Am J Physiol 1999;277:L240-50.
142. Muro S, Taha R, Tsicopoulos A et al. Expression of IL-15 in inflammatory pulmonary diseases. J Allergy Clin Immunol 2001; 108:970-5.
143. Liu Z, Geboes K, Colpaert S et al. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol 2000;164: 3608-15.
144. Sakai T, Kusugami K, Nishimura H et al. Interleukin 15 activity in the rectal mucosa of inflammatory bowel disease. Gastroenterology 1998;114:1237-43.
145. Kirman I, Nielsen OH. Increased numbers of interleukin-15-expressing cells in active ulcerative colitis. Am J Gastroenterol 1996;91:1789-94.
146. Blanco-Jerez C, Plaza JF, Masjuan J et al. Increased levels of IL-15 mRNA in relapsing-remitting multiple sclerosis attacks. J Neuroimmunol 2002;128:90-4.
147. Pashenkov M, Mustafa M, Kivisakk P et al. Levels of interleukin-15-expressing blood mononuclear cells are elevated in multiple sclerosis. Scand J Immunol 1999;50:302-8.
148. Ruckert R, Asadullah K, Seifert M et al. Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J Immunol 2000;165:2240-50.
149. Ong PY, Hamid QA, Travers JB et al. Decreased IL-15 may contribute to elevated IgE and acute inflammation in atopic dermatitis. J Immunol 2002;168:505-10.
150. Ruchatz H, Leung BP, Wei XQ et al. Soluble IL- 15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol 1998;160:5654-60.
151. Villadsen LS, Schuurman J, Beurskens F et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003;112:1571-80.
152. Kim YS, Maslinski W, Zheng XX et al. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity. J Immunol 1998;160: 5742-8.
153. Przepiorka D, Kernan NA, Ippoliti C et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95:83-9.